Pular para o conteúdo
Merck
  • The kinin system in patients with systemic lupus erythematosus exhibiting mucocutaneous lesions: a clinical study.

The kinin system in patients with systemic lupus erythematosus exhibiting mucocutaneous lesions: a clinical study.

Scandinavian journal of immunology (2010-04-14)
R Dellalibera-Joviliano, M L Reis, E A Donadi
RESUMO

In the present study, we evaluated the kinin system components in the plasma of patients with systemic lupus erythematosus exhibiting mucocutaneous lesions. Fifteen women with active cutaneous lupus (P) and 15 normal healthy women (C) were studied. Low molecular (LKg) and high molecular (HKg) weight kininogen were determined by ELISA (expressed microg Bk/ml). The activities of tissue kallikrein (TKal), plasma kallikrein (PKal) and kininase II were assayed by their action on selective substrates. Statistical analysis was performed using the Mann-Whitney test. The patients presented increased plasma levels of LKg (P = 2.98, C = 0.79) and HKg (P = 1.78, C = 0.5) associated with the increased activity of PKal (P = 2.50, C = 1.63 U/ml), TKal (P = 1.87, C = 1.30 microM pNa/ml) and kininase II (P = 1.50, C = 0.51 microM Hys-Leu/ml), when compared to the values observed in the control group (P < 0.0001 for each comparison). Thus, the increased concentration of all parameters of the kinin system in these patients indicate an overactivity of the kinin system in the acute phase of lupus, corroborating with the participation of these mediators in lupus pathogenesis.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Kallikrein from human plasma, buffered aqueous solution, ≥5 units/mg protein